Treatment choices for second-line chemotherapy of metastatic breast cancer

Breast Cancer Research and Treatment

Volumn 81, Issue SUPPL. 1, 2003, Pages

  Zielinski, Christoph C ^a,b  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Breast cancer; Chemotherapy; First line; Metastatic; Second line

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CAPECITABINE; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; MONOCLONAL ANTIBODY; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB;

ALOPECIA; BONE MARROW SUPPRESSION; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG SAFETY; HAND FOOT SYNDROME; HUMAN; METASTASIS; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; SKIN TOXICITY; STANDARD; STOMATITIS; TREATMENT FAILURE; VOMITING;

EID: 0344010622     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/a:1026360621622     Document Type: Conference Paper

References (24)

1. Blum JL, Dieras V, Lo Russo PM, Horton J, Rutman O, Buzdar A, Osterwalder B: Multicenter phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 92: 1759-1768, 2001
2. Blackstein M, Vogel CL, Ambinder R, Cowan J, Iglesias J, Melemed A: Gemcitabine as first line therapy in patients with metastatic breast cancer: a phase II trial. Oncology 62: 2-8, 2002
3. Possinger K, Kaufmann M, Coleman R, Stuart NS, Helsing M, Ohnmacht U, Aming M: Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer. Anticancer Drugs 10: 155-162, 1999
4. Carmichael J, Possinger K, Phillip P, Beykirch M, Kerr H, Walling J, Harris AL: Advanced breast cancer, a phase II trial with gemcitabine. J Clin Oncol 13: 2731-2736, 1995
5. Carmichael J, Walling J: Phase II activity of gemcitabine in advanced breast cancer. Semin Oncol 23: 77-81, 1996
6. Spielmann M, Llombart-Cussac A, Kalla S, Espie M, Namer M, Ferrero JM, Dieras V, Fumoleau P, Cuvier C, Perrocheau G, Ponzio A, Kayitalire L, Pouillart P: Single agent gemcitabine in treated metastatic breast cancer. Oncology 60: 303-307, 2001
7. Brodowicz T, Köstler W, Möslinger R, Tomek C, Vaclavik I, Herscovici V, Wiltschke C, Steger GG, Wein W, Seifert M, Kubista E, Zielinski CC: Single-agent gemcitabine as second-and third-line treatment of metastatic breast cancer. The Breast 9: 338-342, 2000
8. Seidman AD: Gemcitabine as single-agent therapy in the management of advanced breast cancer. Oncology 15: 11-14, 2001
9. Zelek I, Barthier S, Riofrio M, Fizazi K, Rixe O, Delord JP, Le Cesne A, Spielmann M: Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer 92: 2267-2272, 2001
10. Ranson MR, Carmichael J, O'Byrne K, Stewart S, Smith D, Howell A: Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol 15: 3185-3191, 1997
11. Stemmler HJ, Gutschon K, Sommer H, Malekmohammadi M, Kentenich Ch, Forstpointner R, Geuenich S, Bischoff J, Hiddemann W, Heinemann V: Weekly docetaxel (Taxotere) in patients with metastatic breast cancer. Ann Oncol 12: 1393-1398, 2001
12. Perez EA, Vogel CL, Irwin DH, Kirshner II, Patel R: Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 19: 4216-4223, 2001
13. O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, Fumoleau P, Jones S, Lui WY, Mauriac L, Twelves C, Van Hazel G, Verma S, Leonard R: Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20: 2812-2823, 2002
14. Perez-Manga G, Batista N et al.: Efficacy and safety profile of capecitabine in combination with paclitaxel in patients with locally advanced or metastatic breast cancer: preliminary results of a phase II study. Breast Cancer Res Treatm 64: 124, A535, 2000
15. Nagourney RA, Link JS, Blitzer JB, Forsthoff C, Evans SS: Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients. J Clin Oncol 18: 2245-2249, 2000
16. Nicolaides C, Dimopoulos MA, Samantas E, Bafaloukos D, Kalofonos C, Fountzilas G, Razi E, Kosmidis P, Pavlidis N: Gemcitabine and vinorelbine as a second-line treatment in patients with metastatic breast cancer progressing after first-line taxane-based chemotherapy: a phase II study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 11: 873-875, 2000
17. Zielinski CC: Gemcitabine/anthracycline combinations in metastatic breast cancer. Clin Breast Cancer 3: 30-33, 2002
18. Nole F, Catania C, Mandala M, Munzone E, Rocca A, Zampino G, Minchella I, Noberasco C, Colleoni M, Marocco E, Lambiase A, Goldhirsch A: Phase I study of vinorelbine and capecitabine in advanced breast cancer. Proc Am Soc Clin Oncol 428, 2000
19. Norris B, Pritchard KI, James K, Myles D, Bennett K, Marlin S, Skillings J, Findlay B, Vandenberg T, Goss P, Latreille J, Rudinskas L, Lofters W, Trudeau M, Osoba D, Rodgers A: Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA 8. J Clin Oncol 18: 2385-2394, 2000
20. Berruti A, Sperone P, Bottini A, Gorzegno G, Lorusso V, Brunelli A, Botta M, Tampellini M, Donadio M, Mancarella S, De Lena M, Alquati P, Dogliotti L: Phase II study of vinorelbine with protracted fluorouracil infusion as a second-or third-line approach for advanced breast cancer patients previously treated with anthracyclines. J Clin Oncol 18: 3370-3377, 2000
21. Martin M, Lluch A, Casado A, Garcii A, Carbonero I, de Paz L, Esteban C, Insa A, Alfonso R, Garcia-Conde J, Diaz-Rubio E: Paclitaxel plus vinorelbine: an active regimen in metastatic breast cancer patients with prior anthracycline exposure. Ann Oncol 11: 85-89, 2000
22. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Liebermann G, Slamon DJ: Multinational study of the efficacy and safety of humanized anti-HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17: 2639-2648, 1999
23. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Trpathy D, Baly D, Baughman SA, Twaddel T, Glapsy JA, Slamon DJ: Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/ neu monoclonal antibody plus cisplatin in patients with HER2/ neu-overexpressed metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16: 2659-2671, 1998
24. O'Shaughnessy J, Vukelja SJ, Marsland T, Kimmel G, Ratnam S, Pippen J: Phase II trial of gemcitabine plus trastuzumab in metastatic breast cancer patients previously treated with chemotherapy: preliminary results. Clin Breast Cancer 3: 17-20, 2002